Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling

• Published in: NPJ systems biology and applications Vol. 6; no. 1; p. 28
• Main Authors: Hosseini, Iraj, Gadkar, Kapil, Stefanich, Eric, Li, Chi-Chung, Sun, Liping L., Chu, Yu-Waye, Ramanujan, Saroja
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 28.08.2020; Nature Publishing Group
• Subjects: 631/154/436/1729; 631/154/436/2388; 631/250; 631/553/2393; 692/4028/67; Antitumor activity; Bioinformatics; Biomedical and Life Sciences; Bispecific antibodies; CD20 antigen; CD3 antigen; Cell activation; Computational Biology/Bioinformatics; Computer Appl. in Life Sciences; Cytokines; Dosage; Interleukin 6; Life Sciences; Lymphocytes B; Lymphocytes T; Lymphoid tissue; Monoclonal antibodies; Non-Hodgkin's lymphoma; Systems Biology; Targeted cancer therapy

Mosunetuzumab, a T-cell dependent bispecific antibody that binds CD3 and CD20 to drive T-cell mediated B-cell killing, is currently being tested in non-Hodgkin lymphoma. However, potent immune stimulation with T-cell directed therapies poses the risk of cytokine release syndrome, potentially limitin...